William Roper - DaVita HealthCare Independent Director
DVA Stock | USD 136.85 1.60 1.18% |
Director
Dr. William L. Roper, M.D., MPH, serves as Independent Director of the DaVita HealthCare Partners Inc. Dr. Roper was one of our directors since May 2001. In January 2019, Dr. Roper became interim president of the University of North Carolina System, North Carolina system of public higher education. Prior to that, Dr. Roper was chief executive officer of the University of North Carolina Health Care System, dean of the UNC School of Medicine and vice chancellor for medical affairs of UNC since March 2004. Dr. Roper has also served on the board of directors of Cigna Corporationrationration, a health services corporation, since December 2018. Dr. Roper also continues to serve as a professor of health policy and administration in the UNC School of Public Health and a professor of pediatrics and of social medicine in the UNC School of Medicine. From 1997 until March 2004, he was dean of the UNC School of Public Health. Before joining UNC in 1997, Dr. Roper served as senior vice president of Prudential Health Care. He also served as director of the Centers for Disease Control and Prevention from 1990 to 1993, on the senior White House staff in 1989 and 1990 and as the administrator of Centers for Medicare Medicaid Services from 1986 to 1989. Dr. Roper was a member of and is the immediate past chairman of the board of the National Quality Forum, a nonprofit organization that aims to improve the quality of healthcare. From December 2007 to November 2011, Dr. Roper served on the board of Medco Health Solutions, Inc., a pharmacy benefits management company, and from November 2011 until December 2018 served on the board of its successor company, Express Scripts Holding Company since 2001.
Age | 69 |
Tenure | 23 years |
Phone | 720 631 2100 |
Web | https://www.davita.com |
DaVita HealthCare Management Efficiency
The company has Return on Asset of 0.0592 % which means that on every $100 spent on assets, it made $0.0592 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3853 %, implying that it generated $0.3853 on every 100 dollars invested. DaVita HealthCare's management efficiency ratios could be used to measure how well DaVita HealthCare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Erez Haimovitz | Medigus Ltd ADR | N/A | |
Wesley Schack | Edwards Lifesciences Corp | 74 | |
Moshe Shoham | Microbot Medical | 64 | |
Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
Yoav Waizer | Microbot Medical | 51 | |
Steven Loranger | Edwards Lifesciences Corp | 69 | |
Yair Rabinowitch | Medigus Ltd ADR | 71 | |
Yuval Yanai | Medigus Ltd ADR | 65 | |
Martha Marsh | Edwards Lifesciences Corp | 72 | |
William Link | Edwards Lifesciences Corp | 73 | |
Yair Rabinovitch | Medigus Ltd ADR | 67 | |
Doron Birger | Medigus Ltd ADR | 66 | |
Efrat Venkert | Medigus Ltd ADR | 46 | |
Paul LaViolette | Edwards Lifesciences Corp | 63 | |
Solomon Mayer | Microbot Medical | 62 | |
Aviel Shapira | Medigus Ltd ADR | 61 | |
Leslie Heisz | Edwards Lifesciences Corp | 60 | |
Yoseph Bornstein | Microbot Medical | 65 | |
Jeremy Starkweather | Medigus Ltd ADR | 42 | |
Barbara McNeil | Edwards Lifesciences Corp | 74 | |
Anat Naschitz | Medigus Ltd ADR | N/A |
Management Performance
Return On Equity | 0.39 | ||||
Return On Asset | 0.0592 |
DaVita HealthCare Leadership Team
Elected by the shareholders, the DaVita HealthCare's board of directors comprises two types of representatives: DaVita HealthCare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DaVita. The board's role is to monitor DaVita HealthCare's management team and ensure that shareholders' interests are well served. DaVita HealthCare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DaVita HealthCare's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Hearty, Chief Compliance Officer | ||
Shawn Guertin, Director | ||
Javier Rodriguez, Chief Executive Officer, Director | ||
Paula Price, Independent Director | ||
James Hilger, Interim CFO and Chief Accounting Officer | ||
Paul Diaz, Independent Director | ||
Misha Palecek, Chief Business | ||
Christopher Berry, Group Officer | ||
Jeffrey Giullian, Chief Care | ||
Robert Lang, President International Business | ||
John Nehra, Independent Director | ||
Peter Grauer, Lead Independent Director | ||
Phyllis Yale, Independent Director | ||
Craig Samitt, Executive Vice President; CEO of HealthCare Partners | ||
Robert Margolis, Co-Chairman of the Board | ||
Joseph Mello, COO of HealthCare Partners | ||
Jim Gustafson, Vice President - Investor Relations | ||
John Winstel, Chief Accounting Officer, Group Vice President | ||
Roger Valine, Independent Director | ||
Kenneth Smith, Chief Officer | ||
Gregory Moore, Independent Director | ||
David Roer, Chief Medical Officer - DaVita Integrated Kidney Care | ||
FRCPC MD, Chief Operations | ||
Atul Mathur, Executive Vice President of Global Operations | ||
Joel Ackerman, Chief Financial Officer, Treasurer | ||
Kathleen Waters, Chief Legal and Public Affairs Officer | ||
Pamela Arway, Independent Chairman of the Board | ||
Michael Staffieri, Chief Operating Officer- DaVita Kidney Care | ||
Pascal Desroches, Independent Director | ||
LeAnne Zumwalt, Group Vice President - purchasing and government affairs | ||
Kenny Gardner, Chief People Officer - DaVita Kidney Care | ||
Kim Rivera, Chief Legal Officer | ||
Carol Davidson, Independent Director | ||
Barbara Desoer, Independent Director | ||
Dennis Kogod, CEO of International and President of Healthcare Partners | ||
William Roper, Independent Director | ||
Mihran Naljayan, Chief Medical Officer - Home Modalities | ||
Charles Berg, Independent Director | ||
Jeanine Jiganti, Chief Compliance Officer | ||
Laura Mildenberger, Chief People Officer - Kidney Care | ||
MSc MD, Chief International | ||
Kent Thiry, Chairman, CEO and CEO of Healthcare Partners |
DaVita Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DaVita HealthCare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.39 | ||||
Return On Asset | 0.0592 | ||||
Profit Margin | 0.06 % | ||||
Operating Margin | 0.12 % | ||||
Current Valuation | 22.49 B | ||||
Shares Outstanding | 87.32 M | ||||
Shares Owned By Insiders | 45.06 % | ||||
Shares Owned By Institutions | 51.79 % | ||||
Number Of Shares Shorted | 3.47 M | ||||
Price To Earning | 11.43 X |
Pair Trading with DaVita HealthCare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DaVita HealthCare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DaVita HealthCare will appreciate offsetting losses from the drop in the long position's value.Moving together with DaVita Stock
0.79 | RNLX | Renalytix AI Report 4th of April 2024 | PairCorr |
Moving against DaVita Stock
0.91 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.86 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
0.83 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.71 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
0.62 | MASS | 908 Devices Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to DaVita HealthCare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DaVita HealthCare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DaVita HealthCare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DaVita HealthCare Partners to buy it.
The correlation of DaVita HealthCare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DaVita HealthCare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DaVita HealthCare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DaVita HealthCare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DaVita HealthCare Partners. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for DaVita Stock analysis
When running DaVita HealthCare's price analysis, check to measure DaVita HealthCare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DaVita HealthCare is operating at the current time. Most of DaVita HealthCare's value examination focuses on studying past and present price action to predict the probability of DaVita HealthCare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DaVita HealthCare's price. Additionally, you may evaluate how the addition of DaVita HealthCare to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is DaVita HealthCare's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DaVita HealthCare. If investors know DaVita will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DaVita HealthCare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DaVita HealthCare is measured differently than its book value, which is the value of DaVita that is recorded on the company's balance sheet. Investors also form their own opinion of DaVita HealthCare's value that differs from its market value or its book value, called intrinsic value, which is DaVita HealthCare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DaVita HealthCare's market value can be influenced by many factors that don't directly affect DaVita HealthCare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DaVita HealthCare's value and its price as these two are different measures arrived at by different means. Investors typically determine if DaVita HealthCare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DaVita HealthCare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.